Idelalisib regulatory update

Gilead said FDA accepted for review an NDA for idelalisib to treat refractory indolent non-Hodgkin's lymphoma (NHL). The PDUFA date is Sept. 11. Gilead also said it submitted an NDA to FDA early last ...